Argus Raises Merck Stock Price Target to $170

Merck's stock price target has been raised by Argus from $145 to $170. This move reflects an increase of approximately 17% in the estimated value of Merck's shares. The new target is based on backtested results, which show that a strategy similar to this one would have performed well historically.

However, it's essential to note that backtested performance does not guarantee future actual results. In fact, the source explicitly warns that changes in assumptions can significantly impact the backtested returns presented. Furthermore, actual performance may differ significantly from what is shown by these historical results.